Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $18.00 at JPMorgan Chase & Co.

Teva Pharmaceutical Industries (NYSE:TEVA) had its target price upped by JPMorgan Chase & Co. from $16.00 to $18.00 in a research report report published on Monday, Benzinga reports. They currently have a neutral rating on the stock.

Several other equities analysts have also recently commented on the stock. UBS Group raised their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Jefferies Financial Group raised their price objective on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. Barclays boosted their target price on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st. Argus raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research note on Wednesday, July 10th. Finally, StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $19.67.

Teva Pharmaceutical Industries Stock Performance

TEVA opened at $18.25 on Monday. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 2.52. The business’s 50 day moving average is $18.02 and its 200-day moving average is $16.73. The stock has a market cap of $20.67 billion, a PE ratio of -44.50, a price-to-earnings-growth ratio of 1.32 and a beta of 0.88. Teva Pharmaceutical Industries has a twelve month low of $8.10 and a twelve month high of $19.08.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.03. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. The firm had revenue of $4.16 billion for the quarter, compared to the consensus estimate of $3.99 billion. On average, analysts predict that Teva Pharmaceutical Industries will post 2.33 earnings per share for the current year.

Insider Activity

In related news, insider Eric A. Hughes sold 24,537 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $17.25, for a total value of $423,263.25. Following the transaction, the insider now directly owns 45,060 shares in the company, valued at $777,285. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.55% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Janney Montgomery Scott LLC raised its holdings in shares of Teva Pharmaceutical Industries by 13.6% during the first quarter. Janney Montgomery Scott LLC now owns 1,372,477 shares of the company’s stock valued at $19,366,000 after acquiring an additional 164,614 shares during the period. QRG Capital Management Inc. raised its stake in Teva Pharmaceutical Industries by 53.7% during the 1st quarter. QRG Capital Management Inc. now owns 143,747 shares of the company’s stock valued at $2,028,000 after purchasing an additional 50,247 shares during the period. Capital Wealth Planning LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the first quarter valued at $2,169,000. SG Americas Securities LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 12.0% in the first quarter. SG Americas Securities LLC now owns 610,407 shares of the company’s stock valued at $8,613,000 after purchasing an additional 65,529 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. boosted its position in shares of Teva Pharmaceutical Industries by 30.3% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 206,162 shares of the company’s stock worth $2,909,000 after buying an additional 47,954 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.